Effets secondaires cutanés de l'hydroxyurée : étude prospective de 26 patients consultant dans un service de dermatologie

Idiosyncratic Side Effects of Hydroxyurea in Patients with Sickle Cell Anemia

“…There is one report of a cutaneous rash in a child, but details of this have not been described [10]. In patients with myeloproliferative disorders severe cutaneous and mucosal reactions have been reported and include skin atrophy with associated telangiectasias, dryness, hyperpigmentation of nails, skin, mucosal, stomatitis, glossitis, actinic keratosis, alopecia, melanonychia, squamous cell carcinomas of sun exposed areas, keratoacanthomas, acral erythema, dermatomyositislike changes of hands and ulcers of skin and mucous membranes [11][12][13]. To our knowledge, the rash that we observed has not been described in sickle cell patients receiving HU.…”

Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients

“…4). This has untill now been considered a rare sequel of hydroxyurea therapy and only 24 cases have been reported worldwide 5–13, 15 , . 20 Many patients showed transverse and longitudinal bands on a background of diffuse pigmentation in the same nail as has been noted earlier (Fig.…”

“…The adverse effects of hydroxyurea pertaining to the skin and its appendages have mostly been reported as parts of larger reports on efficacy 3 or in patients with haematological malignancies 4 . In recent years, skin, mucosal and nail pigmentation has been observed in patients taking hydroxyurea, but all of these have been isolated case reports 5–14 Apart from these, other reported cutaneous adverse effects are alopecia, dryness of the skin, leg ulcers, cutaneous atrophy, lichen planus‐like eruption, actinic psoriasis, pseudodermatomyositis, lupus erythematosus‐like syndrome, actinic keratoses, squamous cell carcinomas, oral ulcers, leg oedema, cutaneous vasculitis, fixed drug eruption, palmoplantar keratoderma and thin, brittle nails 15 …”

Toenails melanonychia induced by hydroxyurea

“…HU is a chemotherapeutic agent frequently used in the management of sickle cell anaemia and myeloproliferative disorders such as chronic leukaemia, polycythemia vera and essential thrombocythemia. HU may be responsible for a wide range of cutaneous and mucosal adverse events such as xerosis, cutaneous, mucosal and nail hyperpigmentation, skin atrophy, lichenoid reactions, plantar and palmar keratodermia, alopecia, vasculitis, dermatomyositis like eruption, oral ulcerations, stomatitis, leg ulcers and squamous cell carcinomas [1,2]. Incidence of these side effects taken altogether may concern up to 95% of the patients [2].…”

“…HU may be responsible for a wide range of cutaneous and mucosal adverse events such as xerosis, cutaneous, mucosal and nail hyperpigmentation, skin atrophy, lichenoid reactions, plantar and palmar keratodermia, alopecia, vasculitis, dermatomyositis like eruption, oral ulcerations, stomatitis, leg ulcers and squamous cell carcinomas [1,2]. Incidence of these side effects taken altogether may concern up to 95% of the patients [2]. A wide range of nail changes has been described with HU such as onycholysis, onychodystrophy, brittle atrophic nails, onychoschizia, blue lunula and melanonychia [3][4][5].…”